ID
SGYP

Integral Derivatives’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Integral Derivatives’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,000
Closed -$61K – 1466
2016
Q4 		$61K Sell
10,000
-2,500
-20% -$13.1K ﹤0.01% 1081
2016
Q3 		$69K Buy
12,500
+2,500
+25% +$11.7K ﹤0.01% 958
2016
Q2 		$38K Buy
+10,000
New +$33.9K ﹤0.01% 925

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Integral Derivatives's SGYP Position: Q4 2016 in Review

Integral Derivatives sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2016, closing a stake of 12,100 shares — an estimated $63.2K sold.

Integral Derivatives first reported a position in SGYP in Q2 2016 and held it in 2 quarters. The position peaked at $67K in Q3 2016. 156 funds tracked by Wall St. Rank hold SGYP as of Q4 2016.

  • Integral Derivatives reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2016 after selling out during the quarter.
  • Integral Derivatives sold 12,100 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2016, an estimated $63.2K.
  • Integral Derivatives first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2016 and held it in 2 quarters.
  • Integral Derivatives's Synergy Pharmaceuticals, Inc Common Stock position peaked at $67K in Q3 2016.
  • 156 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2016.

Based on Integral Derivatives's 13F filing for Q4 2016, filed 14 Feb 2017.